| abstract |
The invention discloses the use of activated T cells and blocking antibodies in combination to prepare anti-tumor drugs and the anti-tumor drugs. The activated T cells are T cells isolated from a patient's own tissue or body fluid, and are first subjected to anti-human CD3 antibody differentiation. CD3 + T cells are selected, and then stimulated and activated by anti-human CD3 antibody, anti-human CD28 antibody and human IL-2; the blocking antibodies are anti-SIA-IgG antibody, anti-Siglec-7 antibody, anti-Siglec-9 antibody Any one or more of antibodies, anti-Siglec-10 antibodies and anti-PD-1 antibodies. Compared with activated T cells alone or blocking antibodies alone, the combination therapy has a more obvious therapeutic effect, indicating that the use of blocking antibodies and activated T cells has a synergistic effect, thereby achieving a better anti-tumor effect. |